BioMarin Pharmaceutical (1BMRN) AI Stock Analysis

Company Guidance

BioMarin updated full-year 2026 total revenue guidance to between $3.8 billion and $3.9 billion and non GAAP diluted earnings per share guidance to a range of $2.80 to $3.10; the update reflects approximately $70 million of orders expected between late Q4 and Q1 2027, with more than half of that $70 million being VOXZOGO, while the Inozyme acquisition is expected to reduce full year non GAAP diluted earnings per share by approximately $1.55 and the BMN-450 license agreement by approximately $0.32, including approximately $320 million of acquired IPR&D and ongoing operating expenses for Inozyme and approximately $83 million of primarily upfront acquired IPR&D expense and ongoing operating expenses for BMN-450. BioMarin continues to expect approximately $220 million of non-GAAP cost synergies to be realized fully in 2028, said the deal is accretive actually within 9 months, and is currently tracking to even calendar year accretion in 2026; it also expects VOXZOGO to continue to grow in 2027, with the hypochondroplasia launch contributing and Pombility and Opfolda revenue building into 2027 and beyond.